BELGRADE, SERBIA, Aug. 14 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced today that there is great progress being made with the experimental findings to aid in the suppression or ultimately the cure of Multiple Sclerosis not only in their lab in Belgrade, but around the world. (See unauthorized news link)
In a recent study posted on Aug. 12, 2009 scientists have reversed the Multiple Sclerosis in mice. The study showed the suppression of the immune cells, forcing remission and reversing the disease in mice.
Multiple Sclerosis attacks the central nervous system. The researchers explained that "The new treatment, called GIFT15, is composed of two proteins, GSM-CSF and interleukin-15, that are fused in the lab. Normally, the individual proteins act to stimulate the immune system, but when they're stuck together, the proteins suppress immune response, the researchers explained. They do this by converting B-cells -- a type of white blood cell normally involved in immune response -- into immune suppressive cells."
Dr. Jacques Galipeau and his collegues of the Jewish General Hospital Lady Davis Institute for Medical Research and
Researchers in Belgrade are also making progress via using other methodologies that involve Ribavirin and Tiazofurin. Administration of ribavirin and tiazofurin attenuated proliferation of autoreactive T lymphocytes and their infiltration into the nervous tissue, and thereby prevented myelin destruction. These results are encouraging for the future of MS therapy.
In other company news, The company has received many inquiries from its shareholders and followers visa vie meeting the August 15th Q2 financials filings deadline. Mr. Terry Yuan CEO of HTDS said, "The management has decided to release HTDS consolidated financials today August 14th 2009 shortly after the market closes. The reason for that is twofold.
One, we are very pleased where our share price now sits as of close of business day August 13 2009.We have come a long way from being a sub,sub, penny stock, to a transparent well organized, well capitalized company; together with having the market finally begin to recognize our values, and the work our team is doing in Serbia and here in China. HTDS management's aim is to continue with a good solid pace of adding value to HTDS and our shareholders. Secondly, HTDS management goal is to reward both our long and midterm shareholders, instead of catering to those seeking a daily quick profit. We remind our followers that the Q2 financial numbers, obviously will not reflect the recently announced contracts."
Additional details and information will be released as they become available, via regular news releases or via Pink Sheets filing service.
Safe Harbor Statement:
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved